(177)Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma

INTRODUCTION: (177)Lu-DOTATATE-based peptide receptor radionuclide therapy (PRRT) is a promising therapy for metastatic and/or inoperable pheochromocytoma and paraganglioma (PPGL). We aim to evaluate the efficacy and safety of and identify predictors of response to (177)Lu-DOTATATE therapy in metast...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar Jaiswal, Sanjeet, Sarathi, Vijaya, Samad Memon, Saba, Garg, Robin, Malhotra, Gaurav, Verma, Priyanka, Shah, Ravikumar, Kaur Sehemby, Manjeet, A Patil, Virendra, Jadhav, Swati, Ranjan Lila, Anurag, S Shah, Nalini, R Bandgar, Tushar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487189/
https://www.ncbi.nlm.nih.gov/pubmed/32784267
http://dx.doi.org/10.1530/EC-20-0292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487189/
https://www.ncbi.nlm.nih.gov/pubmed/32784267
http://dx.doi.org/10.1530/EC-20-0292

Ejemplares similares